Innovating Women’s Reproductive Health and Pregnancy Therapeutics
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth.
Between the ages of 15 and 49, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral, potentially best-in-class medicines.
Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical-stage pipeline with multiple development programs focused on treating the symptoms associated with endometriosis and uterine fibroids, improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization, and treating preterm labor.
ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
ObsEva is advancing a robust pipeline of novel, oral, clinical-stage compounds to treat women’s reproductive health conditions from conception to birth.
Unique value proposition with three product candidates in clinical development for four indications.
ADVANCED REPRODUCTIVE THERAPEUTICS PIPELINE
A robust growth strategy is important to a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a meaningful clinical portfolio around multiple reproductive therapeutic assets that can address significant unmet medical needs for millions of women worldwide.
How to contact ObsEva ?» contact us